Cigna Group (NYSE:CI) Upgraded to "Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Cigna Group to “Buy” from “Hold.” Across analysts, the stock carries a “Moderate Buy” consensus rating with an average price target of $337.10.
• Cigna reported quarterly EPS of $7.78, exceeding estimates of $7.60, while revenue rose 6.7% year over year to $70.04 billion. The company guided to fiscal 2026 EPS of approximately $30.45.
• Cigna shares opened at $272.22, with a market capitalization of $71.93 billion; institutional investors own approximately 86.99% of the stock, while insiders sold shares during the latest quarter.

Cigna Group (NYSE:CI - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also weighed in on the company. Raymond James Financial lowered Cigna Group from a "strong-buy" rating to an "outperform" rating and reduced their price objective for the stock from $350.00 to $320.00 in a research report on Monday, August 3rd. Barclays lifted their price target on Cigna Group from $304.00 to $310.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Sanford C. Bernstein boosted their price target on Cigna Group from $371.00 to $381.00 and gave the stock an "outperform" rating in a report on Thursday, July 9th. Wells Fargo & Company upped their price objective on Cigna Group from $305.00 to $307.00 and gave the company an "equal weight" rating in a research note on Friday, July 31st. Finally, Guggenheim raised their price objective on shares of Cigna Group from $338.00 to $361.00 and gave the company a "buy" rating in a report on Friday, July 31st. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $337.10.

Cigna Group Trading Up 2.5%

CI opened at $272.22 on Friday. The company has a market cap of $71.93 billion, a P/E ratio of 11.26, a PEG ratio of 0.91 and a beta of 0.31. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of 0.68. The company's 50 day moving average is $280.33 and its 200-day moving average is $280.27. Cigna Group has a 1-year low of $239.51 and a 1-year high of $315.47.

Cigna Group (NYSE:CI - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The health services provider reported $7.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $7.60 by $0.18. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. The business had revenue of $70.04 billion during the quarter, compared to analysts' expectations of $70.14 billion. During the same period in the prior year, the company earned $7.20 EPS. The firm's quarterly revenue was up 6.7% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Equities research analysts predict that Cigna Group will post 30.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Cigna Group

In other Cigna Group news, insider Nicole S. Jones sold 2,677 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $279.61, for a total transaction of $748,515.97. Following the sale, the insider owned 25,880 shares of the company's stock, valued at approximately $7,236,306.80. This represents a 9.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Everett Neville sold 617 shares of Cigna Group stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $284.05, for a total value of $175,258.85. Following the completion of the transaction, the insider directly owned 5,053 shares of the company's stock, valued at approximately $1,435,304.65. This trade represents a 10.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 22,730 shares of company stock valued at $6,293,359. 0.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cigna Group

Several large investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in shares of Cigna Group by 3.7% during the 2nd quarter. BlackRock Inc. now owns 23,438,250 shares of the health services provider's stock worth $6,461,457,000 after buying an additional 840,098 shares in the last quarter. GQG Partners LLC bought a new position in Cigna Group during the second quarter worth $1,628,918,000. Norges Bank bought a new position in Cigna Group during the fourth quarter worth $1,019,790,000. Bank of America Corp DE grew its holdings in Cigna Group by 8.8% in the first quarter. Bank of America Corp DE now owns 3,182,083 shares of the health services provider's stock worth $848,821,000 after purchasing an additional 256,677 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in Cigna Group by 9.8% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,958,656 shares of the health services provider's stock valued at $814,311,000 after purchasing an additional 263,036 shares in the last quarter. Institutional investors and hedge funds own 86.99% of the company's stock.

About Cigna Group

The Cigna Group NYSE: CI is a global health services company that helps individuals, employers, health plans and government organizations access health care and related services. The company operates primarily through two businesses: Cigna Healthcare, which provides medical, behavioral health, dental and other health benefit products and services, and Evernorth Health Services, which offers pharmacy, care delivery and health benefits solutions.

Evernorth includes Express Scripts, a pharmacy benefit services provider that manages prescription drug benefits and operates home delivery and specialty pharmacy services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.